Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at tumor tissue samples from patients who have undergone surgery for localized kidney cancer.
|Kidney Cancer||Genetic: gene expression analysis Other: immunohistochemistry staining method Other: laboratory biomarker analysis|
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Assessment of Patterns of Expression of VEGF, Matrix Metalloproteinase 2, 9 Activity, E-Cadherin Regulation and CA-9 Activity as Predictors of Aggressive Renal Cell Carcinoma Behavior|
- Relative patterns of expression/activity of five different growth factors/enzymes inherently related to the development of metastatic renal cell carcinoma behavior
Biospecimen Retention: Samples With DNA
|Study Start Date:||May 2008|
|Primary Completion Date:||September 2008 (Final data collection date for primary outcome measure)|
Genetic: gene expression analysis
- To identify consistent patterns of VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity as predictive factors in the development of aggressive tumor behavior in tumor tissue samples from patients with localized clear cell renal cell carcinoma.
OUTLINE: Previously collected tumor tissue samples are examined by immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity). Samples are compared to positive tissue controls (i.e., VEGF- tonsil; E- cadherin-normal breast or endometrium; MMP2- placenta) and a negative control (i.e., isotype matched normal serum) to identify consistent patterns of expression/activity of these factors. Levels of expression are quantified as 5-level scores (0 to 4 scale) and differences between any two areas of a tumor are analyzed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00908739
|Principal Investigator:||David A. Levy, MD||Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center|